MedTrace Logo

Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment.

NCT07209046 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-10-06

No results posted yet for this study

Summary

This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.

Conditions

  • Adults
  • GLP-1

Interventions

DIETARY_SUPPLEMENT

UltraFlora® Triplebiotic

The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of probiotic ( UltraFlora® Triplebiotics, 2 capsules/day) are taken daily with a glass of water.

DIETARY_SUPPLEMENT

Placebo

The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of placebo (2 capsule/day) are taken daily with a glass of water.

Sponsors & Collaborators

  • Metagenics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mieke Van Den Driessche, PhD · Metagenics, Inc.

  • Irfan Qureshi, MD · Metagenics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-06-30
Completion
2026-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07209046 on ClinicalTrials.gov